FDA advisory panel endorses Moderna mRNA flu vaccine that was subject of controversy - The Boston Globe
The Vaccines and Related Biological Products Advisory Committee voted unanimously that the benefits of the vaccine outweigh the risks for both adults aged 50 to 64, and those 65 and older.
Ähnliche Seiten
FDA advisory panel endorses Moderna mRNA flu vaccine that was subject of controversy